241 related articles for article (PubMed ID: 2552209)
21. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
22. Usefulness of a multiple biomarker assay in bronchoalveolar lavage (BAL) and serum for the diagnosis of small cell lung cancer.
Nikliński J; Chyczewska E; Furman M; Kowal E; Laudanski J; Chyczewski L
Neoplasma; 1993; 40(5):305-8. PubMed ID: 8272160
[TBL] [Abstract][Full Text] [Related]
23. [Clinical evaluation of serum NSE and CEA in primary lung cancer patients].
Fukasawa T; Fujisawa T; Yamaguchi Y; Sasaki K; Shiba M; Yusa T; Sakio H; Momiki S; Ogawa T
Gan To Kagaku Ryoho; 1986 May; 13(5):1862-7. PubMed ID: 3010884
[TBL] [Abstract][Full Text] [Related]
24. [Diagnostic significance of carcinoembryonic antigen measurement in bronchial lavage fluids in bronchial carcinoma].
Ma WL
Zhonghua Jie He He Hu Xi Za Zhi; 1990 Dec; 13(6):349-50, 380-1. PubMed ID: 1964877
[TBL] [Abstract][Full Text] [Related]
25. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
26. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
27. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of the measurement of serum neuron-specific enolase levels in patients with lung cancer].
Yumoto Y; Shiota T; Tamai M; Okabe K; Kiura K; Shimoe T; Fujii M
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2089-93. PubMed ID: 3013098
[TBL] [Abstract][Full Text] [Related]
29. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
30. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
31. [Clinical evaluation of serum carbohydrate antigen 19-9 in carcinoma of the lung--a comparison with carcinoembryonic antigen].
Hayashibe A; Kodama T; Nishiwaki Y; Kudou H; Inoue Y; Nukariya N; Kaguraoka H; Kuroki M; Takahashi K; Nishiyama Y
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):711-5. PubMed ID: 3030198
[TBL] [Abstract][Full Text] [Related]
32. Carcinoembryonic antigen (CEA) levels in pleural effusions and sera of lung cancer patients.
Ogushi F; Fukuoka M; Takada M; Tamai S; Sakai N; Negoro S; Okunaka N; Sone S; Tsubura E
Jpn J Clin Oncol; 1984 Sep; 14(3):321-7. PubMed ID: 6090732
[TBL] [Abstract][Full Text] [Related]
33. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
34. [The measurement of SCC antigen in squamous cell carcinoma of the lung].
Masuoka T; Matueda Y; Ookawa H; Watanabe K; Mimoto S
Gan No Rinsho; 1985 Jul; 31(8):914-8. PubMed ID: 4032769
[TBL] [Abstract][Full Text] [Related]
35. [In suspected bronchial cancer are the tumor markers neuron-specific enolase, carcinoembryonic antigen and squamous cell carcinoma antigen, of diagnostic help?].
Jany B; Fischbach W; Chowanetz W
Med Klin (Munich); 1988 Feb; 83(4):121-4, 158. PubMed ID: 3367874
[No Abstract] [Full Text] [Related]
36. [Creatine kinase BB and neuron specific r-enolase as biomarkers for lung cancer].
Usui A; Fujita K; Imaizumi M; Abe T; Inoue K; Matsumoto S; Kato K
Gan No Rinsho; 1987 Nov; 33(14):1763-70. PubMed ID: 2826840
[TBL] [Abstract][Full Text] [Related]
37. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
38. [A clinical study on CA 15-3, CEA, SCC-Ag in patients with squamous cell carcinoma of the lung].
Moriya H; Suzuki S; Aizumi J; Kimura K; Urabe S; Higuci Y; Hoshi K
Rinsho Hoshasen; 1989 Jan; 34(1):63-6. PubMed ID: 2724610
[TBL] [Abstract][Full Text] [Related]
39. [Determination of various tumor markers, with special reference to neuron-specific enolase in lung cancer].
Yano H; Hino M; Nishiwaki Y; Kodama T; Hayashibe A; Kudo H; Inoue Y; Nishiyama Y; Sone Y; Oshima T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):77-83. PubMed ID: 3026257
[TBL] [Abstract][Full Text] [Related]
40. [Clinical significance of CEA levels in lung cancer].
Noge S; Hara N; Ichinose Y; Ishimatsu T; Motohiro A; Etoh K; Miyake J; Ohta M
Gan No Rinsho; 1985 May; 31(6 Suppl):616-22. PubMed ID: 2993691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
